CN102174076A - 用于抑制蛋白酶体酶的化合物 - Google Patents
用于抑制蛋白酶体酶的化合物 Download PDFInfo
- Publication number
- CN102174076A CN102174076A CN201110037869XA CN201110037869A CN102174076A CN 102174076 A CN102174076 A CN 102174076A CN 201110037869X A CN201110037869X A CN 201110037869XA CN 201110037869 A CN201110037869 A CN 201110037869A CN 102174076 A CN102174076 A CN 102174076A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- described compound
- zaz
- hydrogen
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)CC(C(C1(C)OC1)=O)NC(C(CC1=CC=CCC1)NC([C@](CC(C)C)NC(C(CCC1=CCCC=C1)NC(CN1CCCCC1)=O)=*)=O)=O Chemical compound CC(C)CC(C(C1(C)OC1)=O)NC(C(CC1=CC=CCC1)NC([C@](CC(C)C)NC(C(CCC1=CCCC=C1)NC(CN1CCCCC1)=O)=*)=O)=O 0.000 description 8
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (63)
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56234004P | 2004-04-15 | 2004-04-15 | |
US60/562340 | 2004-04-15 | ||
US56909604P | 2004-05-07 | 2004-05-07 | |
US60/569096 | 2004-05-07 | ||
US59940104P | 2004-08-06 | 2004-08-06 | |
US60/599401 | 2004-08-06 | ||
US61015904P | 2004-09-14 | 2004-09-14 | |
US61000204P | 2004-09-14 | 2004-09-14 | |
US61000104P | 2004-09-14 | 2004-09-14 | |
US60/610002 | 2004-09-14 | ||
US60/610001 | 2004-09-14 | ||
US60/610159 | 2004-09-14 | ||
US62057304P | 2004-10-20 | 2004-10-20 | |
US60/620573 | 2004-10-20 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200580019845.4A Division CN101006098B (zh) | 2004-04-15 | 2005-04-14 | 用于抑制蛋白酶体酶的化合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102174076A true CN102174076A (zh) | 2011-09-07 |
Family
ID=34965899
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310512372.8A Pending CN103554222A (zh) | 2004-04-15 | 2005-04-14 | 用于抑制蛋白酶体酶的化合物 |
CN201110037869XA Pending CN102174076A (zh) | 2004-04-15 | 2005-04-14 | 用于抑制蛋白酶体酶的化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310512372.8A Pending CN103554222A (zh) | 2004-04-15 | 2005-04-14 | 用于抑制蛋白酶体酶的化合物 |
Country Status (17)
Country | Link |
---|---|
US (9) | US8129346B2 (zh) |
EP (1) | EP1745064B1 (zh) |
JP (3) | JP5616569B2 (zh) |
CN (2) | CN103554222A (zh) |
AT (1) | ATE494298T1 (zh) |
AU (1) | AU2005238445B2 (zh) |
BR (1) | BRPI0509879A (zh) |
CA (1) | CA2562411A1 (zh) |
CY (1) | CY1117244T1 (zh) |
DE (1) | DE602005025750D1 (zh) |
DK (1) | DK1745064T3 (zh) |
HK (1) | HK1097860A1 (zh) |
IL (3) | IL178400A (zh) |
PL (1) | PL1745064T3 (zh) |
PT (1) | PT1745064E (zh) |
SG (2) | SG152239A1 (zh) |
WO (1) | WO2005105827A2 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710507A (zh) * | 2013-12-11 | 2015-06-17 | 深圳翰宇药业股份有限公司 | 一种卡非佐米的制备方法 |
CN106946981A (zh) * | 2017-03-08 | 2017-07-14 | 南京师范大学 | 一种四肽环氧丙烷衍生物及其制备方法和用途 |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2562411A1 (en) | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for enzyme inhibition |
US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
US7232818B2 (en) * | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
AU2012203602B2 (en) * | 2004-04-15 | 2015-08-27 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
EP2030981B1 (en) | 2004-05-10 | 2014-07-09 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
PL2261236T3 (pl) | 2004-12-07 | 2015-12-31 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
PT1948678E (pt) | 2005-11-09 | 2013-07-16 | Onyx Therapeutics Inc | Compostos para inibição de enzimas |
CA2657213C (en) | 2006-06-19 | 2017-01-03 | Proteolix, Inc. | Peptide epoxyketones for proteasome inhibition |
ES2578905T5 (es) | 2007-10-04 | 2020-03-18 | Onyx Therapeutics Inc | Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
WO2010105363A1 (en) | 2009-03-16 | 2010-09-23 | Andrei Yudin | Cyclic amino acid molecules and methods of preparing the same |
AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
GB0914883D0 (en) | 2009-08-26 | 2009-09-30 | Univ Belfast | Compound |
US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
WO2011136905A2 (en) | 2010-04-07 | 2011-11-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
KR102054329B1 (ko) | 2012-05-08 | 2019-12-10 | 오닉스 세라퓨틱스, 인크. | 펩티드 프로테아좀 억제제 제제화를 위한 사이클로덱스트린 복합체화 방법 |
US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
US10076384B2 (en) | 2013-03-08 | 2018-09-18 | Symple Surgical, Inc. | Balloon catheter apparatus with microwave emitter |
MY175418A (en) | 2013-03-13 | 2020-06-24 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
CA2918530C (en) | 2013-07-19 | 2023-10-03 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers |
CN103360348B (zh) * | 2013-07-25 | 2015-06-24 | 苏州鹏旭医药科技有限公司 | 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法 |
CN105518019A (zh) * | 2013-09-06 | 2016-04-20 | 桑多斯股份公司 | 肽环氧基酮的合成 |
WO2015032622A1 (en) * | 2013-09-06 | 2015-03-12 | Sandoz Ag | Stereoselective synthesis of diols and triols by mannich reaction and their use in the synthesis of carfilzomib |
WO2015121769A1 (en) | 2014-02-13 | 2015-08-20 | Ranbaxy Laboratories Limited | Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate |
EP3166933B1 (en) * | 2014-07-14 | 2018-08-01 | Centrax International Inc. | Epoxyketone compounds for enzyme inhibition |
WO2016046843A1 (en) | 2014-09-24 | 2016-03-31 | Biophore India Pharmaceuticals Pvt. Ltd. | Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide |
US20160115198A1 (en) | 2014-10-27 | 2016-04-28 | Apicore Us Llc | Methods of making carfilzomib and intermediates thereof |
CN107548400A (zh) | 2014-12-02 | 2018-01-05 | 费森尤斯卡比肿瘤学有限公司 | 卡非佐米的纯化方法 |
EP3240575A4 (en) | 2014-12-31 | 2018-07-25 | Dr. Reddy's Laboratories Ltd. | Co-crystal of carfilzomib with maleic acid and process for the preparation of pure carfilzomib |
WO2016116882A2 (en) * | 2015-01-23 | 2016-07-28 | Leiutis Pharmaceuticals Pvt Ltd | Novel compositions of carfilzomib |
WO2016170544A1 (en) * | 2015-04-22 | 2016-10-27 | Msn Laboratories Private Limited | Process for the preparation of (2s)-n-((s)-1-((s)-4-methyl-1-((r)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((s)-2-(2-morpholino acetamido)-4-phenylbutanamido)-4-methylpentanamide |
WO2016170489A1 (en) | 2015-04-24 | 2016-10-27 | Fresenius Kabi Oncology Ltd. | Pharmaceutical compositions of proteasome inhibitor |
ES2888800T3 (es) | 2015-05-21 | 2022-01-07 | Laurus Labs Ltd | Procedimiento mejorado para la preparación de carfilzomib o sales farmacéuticamente aceptables del mismo |
EP3377471A4 (en) | 2015-11-11 | 2019-11-20 | Encycle Therapeutics, Inc. | SYNTHESIS OF FRAGMENTS OF CYCLIC PEPTIDES |
WO2018024645A1 (en) | 2016-08-02 | 2018-02-08 | Synthon B.V. | Process for making carfilzomib |
ES2874683T3 (es) | 2016-09-14 | 2021-11-05 | Fresenius Kabi Oncology Ltd | Un proceso para la purificación de un intermedio de carfilzomib |
EP3939989A1 (en) | 2016-11-11 | 2022-01-19 | Zealand Pharma A/S | Cyclic peptides multimers targeting alpha 4beta 7 integrin |
EP3330260A1 (en) | 2016-12-01 | 2018-06-06 | Enantia, S.L. | Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib |
MX2019013362A (es) | 2017-05-10 | 2020-08-17 | Zealand Pharma As | PÉPTIDOS CÍCLICOS HOMODÉTICOS CON LA INTEGRINA A4ß7 COMO DIANA. |
EP3694878A1 (en) | 2017-09-14 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
CN113185575B (zh) * | 2021-05-11 | 2022-07-12 | 四川大学 | 一种花生抗氧化多肽及其制备方法 |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
JPH01136498A (ja) | 1987-11-21 | 1989-05-29 | Nec Corp | 状態監視用情報伝送装置 |
US5135919A (en) | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
US5441944A (en) | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US4990448A (en) | 1989-08-04 | 1991-02-05 | Bristol-Myers Company | Bu-4061T |
US5071957A (en) | 1989-08-04 | 1991-12-10 | Bristol-Myers Company | Antibiotic BU-4061T |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
IE910713A1 (en) | 1990-03-05 | 1991-09-11 | Cephalon Inc | Chymotrypsin-like proteases |
US5340736A (en) | 1991-05-13 | 1994-08-23 | The President & Fellows Of Harvard College | ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting |
GB9300048D0 (en) | 1993-01-04 | 1993-03-03 | Wellcome Found | Endothelin converting enzyme inhibitors |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US6335358B1 (en) | 1995-04-12 | 2002-01-01 | President And Fellows Of Harvard College | Lactacystin analogs |
WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
SI0932617T1 (en) | 1996-10-18 | 2002-06-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
UA66767C2 (uk) | 1996-10-18 | 2004-06-15 | Вертекс Фармасьютикалс Інкорпорейтед | Інгібітори серин-протеаз, фармацевтична композиція, спосіб інгібування активності та спосіб лікування або профілактики вірусної інфекції гепатиту с |
ATE311872T1 (de) | 1996-12-13 | 2005-12-15 | Zymogenetics Inc | Zusammensetzungen und verfahren zum stimulieren von knochenwachstum |
US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
WO1998056422A1 (en) | 1997-06-13 | 1998-12-17 | The University Of Kansas | Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof |
US6099851A (en) | 1998-06-02 | 2000-08-08 | Weisman; Kenneth M. | Therapeutic uses of leuprolide acetate |
US6838436B1 (en) | 1998-07-10 | 2005-01-04 | Osteoscreen Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
US6902721B1 (en) | 1998-07-10 | 2005-06-07 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone growth |
US6204257B1 (en) | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
BR9914648A (pt) | 1998-10-20 | 2001-11-27 | Millennium Pharm Inc | Processo para monitorar ação medicamentosa deinibidor de proteasoma |
US6492333B1 (en) | 1999-04-09 | 2002-12-10 | Osteoscreen, Inc. | Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors |
US6831099B1 (en) | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
JP2003528039A (ja) * | 1999-10-20 | 2003-09-24 | オステオスクリーン,インコーポレイテッド | 骨および毛成長を刺激するためのプロテアソーム活性のインヒビター |
CA2425632A1 (en) | 2000-10-12 | 2002-04-18 | Viromics Gmbh | Agents for the treatment of viral infections |
JP4412586B2 (ja) | 2002-01-08 | 2010-02-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | エポネマイシンおよびエポキソマイシン類似物およびそれらの用途 |
EP1496916A2 (en) | 2002-04-09 | 2005-01-19 | Greenville Hospital System | Metastasis modulating activity of highly sulfated oligosaccharides |
US20030224469A1 (en) | 2002-06-03 | 2003-12-04 | Buchholz Tonia J. | Methods and kits for assays utilizing fluorescence polarization |
US8198270B2 (en) | 2004-04-15 | 2012-06-12 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
CA2562411A1 (en) * | 2004-04-15 | 2005-11-10 | Proteolix, Inc. | Compounds for enzyme inhibition |
US7232818B2 (en) | 2004-04-15 | 2007-06-19 | Proteolix, Inc. | Compounds for enzyme inhibition |
EP2030981B1 (en) | 2004-05-10 | 2014-07-09 | Onyx Therapeutics, Inc. | Compounds for proteasome enzyme inhibition |
AU2005243140A1 (en) | 2004-05-10 | 2005-11-24 | Proteolix, Inc. | Synthesis of amino acid keto-epoxides |
WO2006045066A2 (en) | 2004-10-20 | 2006-04-27 | Proteolix, Inc. | Labeled compounds for proteasome inhibition |
PL2261236T3 (pl) | 2004-12-07 | 2015-12-31 | Onyx Therapeutics Inc | Kompozycja do hamowania proteasomu |
WO2006099261A2 (en) | 2005-03-11 | 2006-09-21 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
PT1948678E (pt) | 2005-11-09 | 2013-07-16 | Onyx Therapeutics Inc | Compostos para inibição de enzimas |
AR057227A1 (es) | 2005-12-09 | 2007-11-21 | Centocor Inc | Metodo para usar antagonistas de il6 con inhibidores del proteasoma |
DE102006026464A1 (de) | 2006-06-01 | 2007-12-06 | Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma | Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus |
CA2657213C (en) | 2006-06-19 | 2017-01-03 | Proteolix, Inc. | Peptide epoxyketones for proteasome inhibition |
JP4325683B2 (ja) * | 2007-02-14 | 2009-09-02 | セイコーエプソン株式会社 | 画像表示装置、及び画像表示装置の制御方法 |
WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
ES2578905T5 (es) | 2007-10-04 | 2020-03-18 | Onyx Therapeutics Inc | Inhibidores de proteasa epoxi cetona peptídicos cristalinos y la síntesis de ceto-epóxidos de aminoácidos |
AP2011005690A0 (en) | 2008-10-21 | 2011-06-30 | Onyx Therapeutics Inc | Combination therapy with peptide epoxyketones. |
-
2005
- 2005-04-14 CA CA002562411A patent/CA2562411A1/en not_active Abandoned
- 2005-04-14 BR BRPI0509879-3A patent/BRPI0509879A/pt not_active Application Discontinuation
- 2005-04-14 JP JP2007508543A patent/JP5616569B2/ja active Active
- 2005-04-14 SG SG200902548-7A patent/SG152239A1/en unknown
- 2005-04-14 CN CN201310512372.8A patent/CN103554222A/zh active Pending
- 2005-04-14 US US11/578,626 patent/US8129346B2/en active Active
- 2005-04-14 PT PT05735686T patent/PT1745064E/pt unknown
- 2005-04-14 EP EP05735686A patent/EP1745064B1/en active Active
- 2005-04-14 PL PL05735686T patent/PL1745064T3/pl unknown
- 2005-04-14 AU AU2005238445A patent/AU2005238445B2/en active Active
- 2005-04-14 SG SG2012076659A patent/SG185306A1/en unknown
- 2005-04-14 DE DE602005025750T patent/DE602005025750D1/de active Active
- 2005-04-14 CN CN201110037869XA patent/CN102174076A/zh active Pending
- 2005-04-14 AT AT05735686T patent/ATE494298T1/de active
- 2005-04-14 WO PCT/US2005/012740 patent/WO2005105827A2/en active Application Filing
- 2005-04-14 DK DK05735686.7T patent/DK1745064T3/da active
-
2006
- 2006-09-28 IL IL178400A patent/IL178400A/en active IP Right Grant
-
2007
- 2007-05-14 HK HK07105045.7A patent/HK1097860A1/xx unknown
-
2011
- 2011-02-18 CY CY20111100205T patent/CY1117244T1/el unknown
- 2011-09-12 JP JP2011198810A patent/JP2012041346A/ja active Pending
- 2011-12-22 US US13/334,466 patent/US8207126B2/en active Active
- 2011-12-22 US US13/334,469 patent/US8207297B2/en active Active
- 2011-12-22 US US13/334,288 patent/US8207125B2/en active Active
- 2011-12-22 US US13/334,372 patent/US8324174B2/en active Active
- 2011-12-22 US US13/334,263 patent/US8207124B2/en active Active
- 2011-12-22 US US13/334,544 patent/US8207127B2/en active Active
- 2011-12-26 IL IL217210A patent/IL217210A0/en unknown
- 2011-12-26 IL IL217211A patent/IL217211A0/en unknown
-
2012
- 2012-03-02 US US13/411,044 patent/US20120277146A1/en not_active Abandoned
-
2013
- 2013-03-12 US US13/797,740 patent/US20130324459A1/en not_active Abandoned
- 2013-08-05 JP JP2013162017A patent/JP2014012676A/ja active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104710507A (zh) * | 2013-12-11 | 2015-06-17 | 深圳翰宇药业股份有限公司 | 一种卡非佐米的制备方法 |
CN104710507B (zh) * | 2013-12-11 | 2018-08-14 | 深圳翰宇药业股份有限公司 | 一种卡非佐米的制备方法 |
CN106946981A (zh) * | 2017-03-08 | 2017-07-14 | 南京师范大学 | 一种四肽环氧丙烷衍生物及其制备方法和用途 |
CN106946981B (zh) * | 2017-03-08 | 2020-08-21 | 南京陵瑞医药科技有限公司 | 一种四肽环氧丙烷衍生物及其制备方法和用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102174076A (zh) | 用于抑制蛋白酶体酶的化合物 | |
CN101014612B (zh) | 用于酶抑制的化合物 | |
CN102286070B (zh) | 用于抑制蛋白酶体的化合物 | |
CN101506224B (zh) | 蛋白酶体抑制用的肽环氧酮 | |
CN101405294B (zh) | 用于酶抑制的化合物 | |
CN101006098B (zh) | 用于抑制蛋白酶体酶的化合物 | |
CN102892417A (zh) | 用于免疫蛋白酶体抑制的化合物 | |
CN105164117B (zh) | 二肽和三肽环氧酮蛋白酶抑制剂 | |
KR20070086924A (ko) | 프로테아좀 저해를 위한 조성물 | |
CN101044157B (zh) | 用于抑制蛋白酶体的化合物 | |
TR201808563T4 (tr) | Proteazom enzim inhibisyonuna yönelik bileşikler. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1162521 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20131011 Address after: American California Applicant after: Proteolix Inc. Address before: American California Applicant before: Proteolix Inc. |
|
C12 | Rejection of a patent application after its publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110907 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1162521 Country of ref document: HK |